Treatment of impaired respiratory function with gaboxadol

Details for Australian Patent Application No. 2005229493 (hide)

Owner H. Lundbeck A/S

Inventors Ebert, Bjarke; Hedner, Jan; Lundahl, Jonas

Agent Watermark

Pub. Number AU-A-2005229493

PCT Pub. Number WO2005/094820

Priority PA 2004 00540 02.04.04 DK; 60/559,096 02.04.04 US

Filing date 31 March 2005

Wipo publication date 13 October 2005

International Classifications

A61K 31/424 (2006.01) - condensed with heterocyclic ring systems, e.g. clavulanic acid

Event Publications

26 October 2006 PCT application entered the National Phase

  PCT publication WO2005/094820 Priority application(s): WO2005/094820

18 January 2007 Amendment Made

  The nature of the amendment is: Delete priority details 60/559,096 02 Apr 2004 US 2005233643 The University of Utah Research Foundation The nature of the amendment is: Amend the invention title to read Biodegradable and biocompatible PEG-based poly(ester-urenthanes)

28 October 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005229496-Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases

2005229492-Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors